Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.15252/msb.20209628 http://scihub22266oqcxt.onion/10.15252/msb.20209628 32729248!7390914!32729248     free     free     free Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Mol+Syst+Biol 2020 ; 16 (7): e9628 Nephropedia Template TP {{tp|p=32729248|t=2020. In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression |pdf=|usr=}}{{32729248}} gab.com Text In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression JO: Mol Syst Biol http://www.kidney.de/pget.php?&tw=1&pmid=32729248 #FOAvip The COVID-19 pandemic caused by SARS-CoV-2 has is a global health challenge. Angiotensin-converting enzyme 2 (ACE2) is the host receptor for SARS-CoV-2 entry. Recent studies have suggested that patients with hypertension and diabetes treated with ACE inhibitors (ACEIs) or angiotensin receptor blockers have a higher risk of COVID-19 infection as these drugs could upregulate ACE2, motivating the study of ACE2 modulation by drugs in current clinical use. Here, we mined published datasets to determine the effects of hundreds of clinically approved drugs on ACE2 expression. We find that ACEIs are enriched for ACE2-upregulating drugs, while antineoplastic agents are enriched for ACE2-downregulating drugs. Vorinostat and isotretinoin are the top ACE2 up/downregulators, respectively, in cell lines. Dexamethasone, a corticosteroid used in treating severe acute respiratory syndrome and COVID-19, significantly upregulates ACE2 both in vitro and in vivo. Further top ACE2 regulators in vivo or in primary cells include erlotinib and bleomycin in the lung and vancomycin, cisplatin, and probenecid in the kidney. Our study provides leads for future work studying ACE2 expression modulators. Twit Text FOAVip In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression ????Mol Syst Biol http://www.kidney.de/pget.php?&tw=1&pmid=32729248 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32729248 #FOAvip English Wikipedia <ref>{{Cite pmid|32729248}}</ref> In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression #MMPMID32729248 Sinha S; Cheng K; Schaffer AA; Aldape K; Schiff E; Ruppin E Mol Syst Biol 2020[Jul]; 16 (7): e9628 PMID32729248show ga The COVID-19 pandemic caused by SARS-CoV-2 has is a global health challenge. Angiotensin-converting enzyme 2 (ACE2) is the host receptor for SARS-CoV-2 entry. Recent studies have suggested that patients with hypertension and diabetes treated with ACE inhibitors (ACEIs) or angiotensin receptor blockers have a higher risk of COVID-19 infection as these drugs could upregulate ACE2, motivating the study of ACE2 modulation by drugs in current clinical use. Here, we mined published datasets to determine the effects of hundreds of clinically approved drugs on ACE2 expression. We find that ACEIs are enriched for ACE2-upregulating drugs, while antineoplastic agents are enriched for ACE2-downregulating drugs. Vorinostat and isotretinoin are the top ACE2 up/downregulators, respectively, in cell lines. Dexamethasone, a corticosteroid used in treating severe acute respiratory syndrome and COVID-19, significantly upregulates ACE2 both in vitro and in vivo. Further top ACE2 regulators in vivo or in primary cells include erlotinib and bleomycin in the lung and vancomycin, cisplatin, and probenecid in the kidney. Our study provides leads for future work studying ACE2 expression modulators. |A549 Cells[MESH] |Angiotensin Receptor Antagonists/*pharmacology[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Angiotensin-Converting Enzyme Inhibitors/*pharmacology[MESH] |Betacoronavirus[MESH] |Bleomycin/pharmacology[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/*drug therapy[MESH] |Dexamethasone/pharmacology[MESH] |Drug Design[MESH] |Drug Evaluation, Preclinical[MESH] |Erlotinib Hydrochloride/pharmacology[MESH] |Fluphenazine/pharmacology[MESH] |HEK293 Cells[MESH] |Humans[MESH] |Kidney/drug effects[MESH] |Lung/drug effects[MESH] |MCF-7 Cells[MESH] |Pandemics[MESH] |Peptidyl-Dipeptidase A[MESH] |Pneumonia, Viral/*drug therapy[MESH] |SARS-CoV-2[MESH] |Systems Biology[MESH] |Up-Regulation[MESH]In vitro and in vivo identification of clinically approved drugs that (epmc).pdf DeepDyve Pubget Overpricing